Glutathione is a thiol-disulfide exchange peptide critical for buffering oxidative or chemical stress, and an essential cofactor in several biosynthesis and detoxification pathways. The rate-limiting step in its de novo biosynthesis is catalyzed by glutamate cysteine ligase, a broadly expressed enzyme for which limited structural information is available in higher eukaryotic species. Structural data are critical to the understanding of clinical glutathione deficiency, as well as rational design of enzyme modulators that could impact human disease progression. Here, we have determined the structures of Saccharomyces cerevisiae glutamate cysteine ligase (ScGCL) in the presence of glutamate and MgCl₂ (2.1 Å; R = 18.2%, Rₚ = 21.9%), and in complex with glutamate, MgCl₂, and ADP (2.7 Å; R = 19.0%, Rₚ = 24.2%). Inspection of these structures reveals an unusual binding pocket for the α-carboxylate of the glutamate substrate and an ATP-independent Mg²⁺ coordination site, clarifying the Mg²⁺ dependence of the enzymatic reaction. The ScGCL structures were further used to generate a credible homology model of the catalytic subunit of human glutamate cysteine ligase (hGCLC). Examination of the hGCLC model suggests that post-translational modifications of cysteine residues may be involved in the regulation of enzymatic activity, and elucidates the molecular basis of glutathione deficiency associated with patient hGCLC mutations.

Glutathione, γ-glutamylcysteinylglycine, is a low molecular weight thiol, central to maintenance of redox homeostasis. Among its normal functions are the scavenging of reactive oxygen and nitrogen species (1), storage and transport of cysteine (2, 3), leukotriene, and prostaglandin biosynthesis (4, 5), and regulation of enzyme activity via reduction of disulfide bonds and glutathionylation (6, 7). Disruption of glutathione metabolism is associated with the progression of AIDS, cancer, and neurodegenerative conditions such as Parkinson and Alzheimer disease (8–12). Polymorphisms that reduce activity of glutamate cysteine ligase (GCL),² the first and rate-limiting enzyme in de novo synthesis of glutathione, are correlated with reduced glutathione levels in patients with hemolytic anemia, schizophrenia and other neurological disorders (13–16). Given its importance both in normal and disease states, there is considerable interest in the development of novel compounds that could be used to modulate intracellular glutathione levels, potentially via GCL.

Glutathione is synthesized from its three constituent amino acids by consecutive action of two cytosolic ATP-dependent enzymes: GCL and glutathione synthetase (17). GCL catalyzes the conjugation of the γ-carboxyl group of L-glutamate to the amino group of L-cysteine (17). The proposed catalytic mechanism proceeds via phosphorylation of the γ-carboxylate of L-glutamate by ATP (18–20). The α-amino group of L-cysteine acts as a nucleophile, attacking the γ-glutamyl phosphate intermediate to produce γ-glutamylcysteine. This dipeptide is then coupled in an analogous fashion to glycine by glutathione synthetase to generate glutathione. As the committed step of glutathione biosynthesis, GCL activity is regulated by L-cysteine availability (21), feedback inhibition by glutathione (22), and transcriptional and post-translational regulation (23).

Based on sequence analysis, three distinct groups of GCL have been identified. Groups 1 and 3 are comprised of bacterial and plant orthologues (24). Recently, x-ray crystal structures of Escherichia coli (Group 1) (25) and Brassica juncea (Group 3) (26) GCL were described, providing the first structural insights into γ-glutamylcysteine synthetase. However, low sequence identity (<10%) between enzymes of different groups has precluded translation of these structural data into a detailed understanding of the molecular features of enzymes in Group 2, the class that encompasses yeast and mammalian GCL. One structurally unique feature of several Group 2 GCL is the potential for higher order regulation imposed by their existence in reversible heterodimeric complexes of a catalytic (GCLC) and a modulatory subunit (GCLM) (17). To circumvent the inherent challenges associated with structural studies of the complex, we selected the monomeric Saccharomyces cerevisiae GCL (ScGCL), a member of a unique subclass of Group 2 GCL, as a model system for higher eukaryotic GCL. Although ScGCL differs from human GCLC in its oligomeric state, the two enzymes share ~45% sequence identity (24).

* This work was supported, in whole or in part, by National Institutes of Health Grant Number 1R01 GM077289 (to J. J. B.).

The atomic coordinates and structure factors (codes 3IG5 and 3IG8) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

The on-line version of this article (available at http://www.jbc.org/) contains supplemental Figs. S1 and S2.

To whom correspondence should be addressed: Dept. of Biochemistry and Redox Biology Center, University of Nebraska, 1901 Vine St., Lincoln, NE 68588-0664. Tel.: 402-472-9307; Fax: 402-472-7842; E-mail: jbarycki2@unl.edu.

¹ The abbreviations used are: GCL, glutamate cysteine ligase; DTT, dithiothreitol; r.m.s.d., root mean-square deviation; AMP-PNP, adenosine 5’-[(β,γ-imido)triphosphate; PDB, Protein Data Bank; MES, 2-(N-morpholino)ethanesulfonic acid; PEG, polyethyleneglycol.

² The JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 47, pp. 32700 –32708, November 20, 2009 © 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

32700 JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanistic Details of Glutathione Biosynthesis Revealed by Crystal Structures of Saccharomyces cerevisiae Glutamate Cysteine Ligase*¹

Ekaterina I. Biterova and Joseph J. Barycki¹

From the Department of Biochemistry and the Redox Biology Center, University of Nebraska, Lincoln, Nebraska 68588-0664

Received for publication, May 25, 2009, and in revised form, August 14, 2009 Published, JBC Papers in Press, September 2, 2009, DOI 10.1074/jbc.M109.025114
In the current study, we present the crystal structures of ScGCL in complex with glutamate and Mg$^{2+}$, as well as in the presence of glutamate, Mg$^{2+}$, and ADP. Examination of these structures provides considerable insights into catalysis and reveals a unique coordination at the α-carboxylate of the glutamate substrate. Based on the ScGCL structure, a homology model of human GCLC was generated to investigate the molecular details of several human patient mutations with reduced activity, and to aid in the design of novel modulators of GCL activity.

**EXPERIMENTAL PROCEDURES**

**Generation of ScGCL Expression Construct**—A predicted open reading frame in the *S. cerevisiae* genome (KEGG Data Base Entry YJL101C) (27, 28) was amplified by the polymerase chain reaction using *S. cerevisiae* genomic DNA (American Type Culture Collection) as a template. Designed primers contained SpeI (forward) and SalI (reverse) restrictions sites. The resultant 2-kb product was digested with the relevant enzymes and ligated into a complementarily digested pET-21a(+) expression vector (Novagen; NheI and SalI), thus incorporating a C-terminal histidine tag. The expression construct was sequenced at the Genomics Facility of University of Nebraska (Lincoln, NE) and confirmed to be identical to the YJL101C sequence.

**Protein Expression and Purification**—The ScGCL construct was used to transform *Escherichia coli* Rosetta®(DE3) pLysS cells (Novagen). Cells were grown in 2xYT medium containing 100 μg ml$^{-1}$ ampicillin and 34 μg ml$^{-1}$ chloramphenicol at 37 °C, and ScGCL production was induced by the addition of 500 μM isopropyl-1-thio-β-D-galactopyranoside once the cells reached an A$_{600}$ of 0.6. After induction, cultures were grown for 4 h at 30 °C. Cells were harvested by centrifugation (20 min, 8000 × g, 4 °C) and stored at −80 °C. Frozen cell pellets were thawed, resuspended in lysis buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM NaCl, 0.2 mM protease inhibitor, 10 mM imidazole), and disrupted by sonication. Following centrifugation to remove cellular debris (30 min, 20,000 × g, 4 °C), the supernatant was loaded onto a HisTrap Chelating HP Column (GE Healthcare) equilibrated with lysis buffer. The column was washed to baseline (A$_{280}$), and the remaining bound proteins were eluted using a linear imidazole gradient (10–250 mM). Fractions containing ScGCL were pooled, concentrated, and loaded onto a Sephacryl 200 gel filtration column (16 × 600 mm) equilibrated with 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, and 2 mM DTT. Samples containing ScGCL were pooled and dialyzed against crystallization buffer (20 mM Tris-HCl, pH 7.4, 2 mM DTT). The enzyme was concentrated to 12 mg ml$^{-1}$ using an Amicon ultrafiltration device (Stirred cell 8050, 10-kDa cutoff), flash-frozen in liquid nitrogen, and stored at −80 °C. The enzyme concentration was determined by absorbance (280 nm) using a calculated extinction coefficient (29) of 105,200 M$^{-1}$ cm$^{-1}$.

**Characterization of ScGCL**—ScGCL was examined by analytical gel filtration chromatography on a Superdex 200 HR 10/30 column (GE Healthcare, equilibrated with 20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM DTT). Molecular weight determinations were made by comparison with the following standards: thyroglobulin, 699 kDa; ferritin, 416 kDa; catalase, 219 kDa; aldolase, 176 kDa; albumin, 67 kDa; ovalbumin, 47 kDa; chymotrypsinogen A, 20 kDa; RNase A, 15 kDa (GE Healthcare). Enzymatic activity was measured in the presence of 20 mM L-glutamate, 10 mM L-cysteine, 5 mM ATP, and 50 mM MgCl$_2$ using an indirect assay that couples ADP production to NADH oxidation (30).

**Structure Determination of ScGCL**—Initial crystallization screening was performed by the sitting-drop vapor-diffusion method using sparse matrix crystal screens (Qiagen). Crystals of ScGCL (7 mg/ml) were ultimately grown at 18 °C out of a solution of 12% (w/v) PEG 400, 100 mM MES, pH 6.8, and reached the dimensions 0.15 × 0.15 × 0.15 mm. Once suitable crystallization conditions were established, several complexes were co-crystallized as indicated below.

An extensive search of potential heavy metal derivatives was conducted and a derivative suitable for phasing was identified. ScGCL was incubated with 1 mM trimethyl lead acetate, 5 mM L-glutamate, 5 mM ATP, and 20 mM MgCl$_2$ and co-crystallized. Crystals were transferred into an appropriate stabilizing solution, containing 100 mM MES, pH 6.8, 5 mM ATP, 5 mM L-glutamate, 20 mM MgCl$_2$, and 30% PEG 400 and vitrified in the cryostream (X-Stream cooling system; Rigaku) (31). Diffraction data were collected using radiation produced by a Rigaku MicroMax-007 x-ray generator fitted with confocal blue optics and an R-axis IV++ image plate system (λ = 1.54 Å; 100 K). Data were processed with the HKL2000 software package (32).

The structure of ScGCL derivatized with trimethyl lead acetate was solved using experimental phases determined by single wavelength anomalous diffraction utilizing the PHENIX software suite (33). A readily interpretable electron density map was obtained, and automated model building was employed. The initial model contained a single Pb$^{2+}$ bound at the enzyme active site. Since the Pb$^{2+}$ occupied one of the three Mg$^{2+}$ binding sites, M2 (see below), this initial model was used only as a search probe for subsequent ScGCL complex structure determinations.

To examine the structural basis of catalysis and substrate recognition, several ScGCL complexes were pursued. ScGCL was incubated with 5 mM L-glutamate, 5 mM AMP-PNP, 5 mM L-cysteine, and 20 mM MgCl$_2$, or 5 mM L-glutamate, 5 mM ADP, 5 mM L-cysteine, and 20 mM MgCl$_2$ and both complexes were crystallized. Crystals were transferred to a suitable cryosolution (30% PEG 400, 100 mM MES, pH 6.8, and the appropriate ligands) and then stored in liquid nitrogen. Diffraction data (λ = 0.9 Å; 100 K) were collected on Beaml ine 14-BM-C of BioCARS at Argonne National Laboratory’s Advanced Photon Source and were processed with the HKL2000 software package (32).

The structures were solved by molecular replacement within the PHENIX software suite (33) using the initial ScGCL model as a probe. Iterative rounds of model building and refinement were carried out using Coot (34) and Refmac5 (35) respectively. As the protein models neared completion, water molecules obeying proper hydrogen-bonding constraints with electron density greater than 1.0 σ on a 2F$_o$−F$_c$ map and 4.0 σ on an F$_o$−F$_c$ map were also included in the final structure. Model geometry was monitored using MOLPROBITY (36), and fig-
ures were produced using Chimera (37). To validate the location of the metal binding sites, ScGCL was crystallized in the presence of 5 mM L-glutamate, 5 mM ADP, 5 mM L-cysteine, and 20 mM MnCl\(_2\). Diffraction data were collected using radiation produced by a Rigaku MicroMax-007 x-ray generator fitted with confocal blue optics and an R-axis IV image plate system (\(\lambda = 1.54 \text{ Å}; 100 \text{ K})). Data were processed with the HKL2000 software package (32) and an anomalous difference map was calculated.

**RESULTS**

**Characterization of ScGCL**—ScGCL was purified from *E. coli* with a specific activity of \(\sim 10 \text{ µmoles/min/mg of protein, comparable to other glutamate cysteine ligases. Both analytical gel filtration chromatography as well as sedimentation velocity experiments indicated that ScGCL was likely a monomer in solution (data not shown). As discussed below, a single polypeptide chain is contained within the asymmetric unit of ScGCL crystals, and relatively modest interactions between crystallographically related molecules are observed, consistent with a monomeric enzyme. Although GCL is typically a heterodimer comprised of a catalytic subunit and a modifier subunit in higher eukaryotes (Group 2), phylogenetic analysis suggests that members of the hemiascomycete class of fungi do not have a modifier subunit and that ScGCL likely functions as a monomer in *vivo*.**

**Overall Structure of ScGCL**—Phase information was obtained using single wavelength anomalous diffraction data collected from a crystal of ScGCL derivatized with trimethyl lead acetate (Table 1). The PHENIX software suite (33) was used to identify the positions of one lead (coincident with the M2 binding site described below) and each of the ordered 22 sulfur atoms in the final model (8 of 9 cysteine residues; 14 of 15 methionine residues), and to calculate an initial experimentally phased map. ScGCL crystals have a calculated solvent content of \(\sim 65%\) and density modification in PHENIX significantly improved the experimental phases (supplemental Fig. S1). Automated chain tracing resulted in a model that contained \(\sim 90%\) of the ScGCL sequence. This initial model was used for subsequent structure determinations of the ScGCL complexes by molecular replacement. ScGCL was also crystallized in the presence of L-glutamate, AMP-PNP, cysteine, and Mg\(^{2+}\), or L-glutamate, ADP, cysteine, and Mg\(^{2+}\). Data sets were collected to 2.1 Å and 2.7 Å, respectively (Table 1). However, convincing electron density was not observed for either AMP-PNP or cysteine. Refinement statistics for the final ScGCL models, corresponding to residues 2 through 676, are provided in Table 1. The ScGCL/Glu/Mg\(^{2+}\) and the ScGCL/Glu/Mg\(^{2+}\)/ADP complexes have 99.7 and 99.0% of residues, respectively, in the allowed region of the Ramachandran plot as assessed by MOLPROBITY (36).

A single polypeptide chain is contained within the asymmetric unit of ScGCL crystals, and relatively modest interactions between crystallographically related molecules are observed, consistent with a monomeric enzyme. The ScGCL fold (Fig. 1) shows strong structural similarity to other members of the ATP-grasp superfamily, and has a core \(\beta\)-sheet comprised of six anti-parallel \(\beta\)-strands surrounded by \(\alpha\)-helices. The N terminus of the protein defines a lip of the active site, which is situated in a central cavity of the protein. Despite low sequence identity (\(\sim 10%\)), the core fold of the ScGCL structure is similar...
to those of the previously determined *E. coli* (25) (2D32; rmsd 2.3 Å for 266 Cα atoms) and *B. juncea* (26) (2GWD; r.m.s.d. 2.0 Å for 321 Cα atoms) GCL structures with several differences of note (Fig. 1). The larger ScGCL structure (678 residues), relative to the bacterial (518 residues) and plant (514 residues) homologues, contains three additional short β-sheets formed by anti-parallel β-strands, as well as extended α-helical and loop regions.

An intriguing feature of the structure is a cysteine residue, Cys-70, that appears to be oxidized to sulfenic acid (supplemental Fig. S2). As discussed below, there are several prominent cysteine residues in ScGCL, suggesting that cysteine oxidation and/or additional post-translational modifications may play an important regulatory role. In support of this hypothesis, previous studies have shown that H2O2 increases the enzymatic activity of GCL (38, 39). However, the mechanism of this activation was not demonstrated, and additional studies are needed to clarify the functional significance of Cys-70 oxidation.

**Identification of the L-glutamate Binding Site and an ATP-independent Bound Mg2⁺ Cofactor**—In the ScGCL structure, L-glutamate is bound in the extended conformation in the interior of the funnel-shaped active site cavity (Fig. 2A), with the side chains of Arg-313 and Tyr-362 positioning the α-carboxylate of the glutamate substrate. The α-amino group of glutamate is within hydrogen bond distance of the backbone carbonyl of Cys-264, the γ-carboxylate of Glu-52, and a bound water molecule, which is positioned by the carboxylate of Glu-96 and the backbone carbonyl of Met-262. The γ-carboxylate of the glutamate substrate occupies one of the coordination sites of an interesting Mg2⁺ cofactor (discussed below) and is in close proximity to the side chain of Arg-472. An additional feature of the glutamate-binding pocket is Cys-266, which is stacked 3.2 Å below the α-carboxylate carbon atom.

Interestingly, despite the absence of ATP, electron density was also observed for an octahedrally coordinated Mg2⁺ at the enzyme active site. The bound Mg2⁺ is within 2.2 Å of two active site glutamate residues, Glu-52 and Glu-103, and near the γ-carboxylate of the glutamate substrate (Fig. 2B). A fourth glutamate, Glu-96, and an ordered water molecule, positioned by Glu-50, are also located adjacent to the bound magnesium ion (2.6 Å and 2.4 Å, respectively). A water molecule occupies the final coordination site (1.9 Å), but its corresponding electron density is poorly defined. As discussed below, binding of ADP is accompanied by the formation of two additional magnesium binding sites.

**Identification of the ADP Binding Site and Examination of the Metal Coordination**—Since convincing electron density was not observed for the non-hydrolyzable ATP analogue in the active site of the initial ScGCL/Glu/Mg2⁺ complex, a second data set was collected in which ADP replaced AMP-PNP (Table 1). In the ScGCL/Glu/Mg2⁺/ADP complex, ADP is largely solvent-exposed, with its adenine ring on the outer edge of the active site pocket, and its β-phosphate positioned near the γ-carboxylate of the bound glutamate substrate. Relatively few hydrogen bonds anchor the adenosine portion of the molecule (Fig. 3A). The N6 atom of the adenine ring is within hydrogen bond distance of the side chain of Glu-272. The 2′-hydroxyl group of the ribose ring interacts with the backbone carbonyl of Pro-106 via a bridging water molecule, and the 3′-hydroxyl group is within hydrogen bond distance of the backbone carboxyl of Asp-49. In addition, the 3′-hydroxyl group forms a hydrogen bond with a structurally conserved water molecule that is held in place by hydrogen bonds to the backbone carboxyl of Gly-48 and the side chains of Thr-270 and Glu-50. Lys-451, via bridging water molecules, appears to contribute to the orientation of the β-phosphate. However, the most striking interactions of this terminal phosphate are with two bound magnesium ions, M2 and M3 (Fig. 3).
Structure of Glutamate Cysteine Ligase

Three bound metal ions were identified in the ScGCL/Glu/ Mg$^{2+}$/ADP complex. The first metal binding site, M1, is comparable to the Mg$^{2+}$ site identified in the initial ScGCL/Glu/ Mg$^{2+}$ complex. As before, the γ-carboxylates of Glu-52, Glu-103, and the glutamate substrate are within 2.2 Å of the metal. The side chain carboxylate of Glu-96 moves ~0.4 Å closer to the M1 metal site, and is also positioned ~2.2 Å from the bound Mg$^{2+}$. The two bound water molecules seen in the ScGCL/Glu/Mg$^{2+}$/ADP complex are absent in the ScGCL/Glu/Mg$^{2+}$/ADP complex. The binding of ADP results in the formation of two additional Mg$^{2+}$ sites. The second site, M2, is created by the side chain oxygen atoms of Gln-268, Glu-470, and Glu-50 as well as an oxygen atom from the β-phosphate of ADP. Similarly, the third Mg$^{2+}$, M3, is coordinated by side chain oxygen atoms of Glu-103 and Glu-50 as well as an oxygen atom from the β-phosphate of ADP. The γ-phosphate of ATP would likely bind adjacent to the γ-carboxylate of the glutamate substrate, positioned optimally for catalysis by the three bound Mg$^{2+}$ ions.

To confirm the placement of the three Mg$^{2+}$ in the final ScGCL/Glu/ Mg$^{2+}$/ADP complex model, a comparable data set in which the Mg$^{2+}$ was replaced with Mn$^{2+}$ during crystallization was collected (Table 1). Mn$^{2+}$ has been shown to support catalysis by glutamate cysteine ligase (40) and has a significant anomalous signal at a wavelength of 1.54 Å (K edge at 1.89 Å). An anomalous difference map was calculated and examined (Fig. 3B). Three major peaks (>8σ) were identified, presumably corresponding to each of the three bound Mn$^{2+}$ ions, which superimpose well on the three bound Mg$^{2+}$ in the final ScGCL/Mg$^{2+}$/ADP/Glu complex model. The interatomic Mg$^{2+}$ distances are 4.75 Å between M1 and M2, 4.06 Å between M2 and M3, and 3.36 Å between M1 and M3.

Homology Modeling of the Human Glutamate Cysteine Ligase Catalytic Subunit (hGCLC)—There have been several published attempts to generate a homology model of hGCLC using either the functionally related T. thermophilus glutamyl-tRNA synthetase or E. coli YbdK (41, 42). However, comparison of these models with the ScGCL structure reported herein shows significant structural dissimilarities, revealing the limitations of models derived from such distant homologues. Using the PDB-Viewer software package (43), a homology model of hGCLC was generated (Fig. 4) that retains the overall fold of ScGCL. Several regions of the hGCLC sequence (residues 210–223, 312–324, 490–507) have low sequence identity to ScGCL. These regions correspond to poorly defined surface loops (shown in green) in the final hGCLC model. Comparison of the active sites of the hGCLC homology model and the ScGCL structure indicates that the two enzymes have nearly identical active site architectures with almost complete conservation of side chain functionality. A remarkable feature of the hGCLC model is that the fourteen cysteine residues of the protein are located primarily in a single hemisphere of the protein. Several of these solvent-exposed cysteine residues may be important for the post-translational regulation of hGCLC activity. Atomic coordinates and structural factors have been deposited in the PDB under accession codes 3IG5 and 3IG8.

DISCUSSION

Glutathione is a vital cellular reductant and a critical biological cofactor. GCL catalyzes the rate-limiting step in its biosyn-
A unique feature of the ScGCL active site is the placement of a cysteine residue, Cys-266, proximal to the α-carboxylate of the glutamate substrate (Fig. 4). This residue is highly conserved among higher eukaryotic GCL and its importance has been examined in a number of homologues (45, 46). Previous modeling studies of human GCL indicated that Cys-249, analogous to Cys-266 of ScGCL, was located in the periphery of the enzyme active site and not directly involved in substrate binding or catalysis (41). However, our model of hGCL suggests that Cys-249 is located at the base of the glutamate-binding pocket. Further support for an active role is provided by mutational analysis of hGCL in which Cys-249 was substituted with a glycine, resulting in a 10-fold reduction in enzymatic activity (47). Similarly, a C248A/C249A double mutant in the mouse GCL catalytic subunit resulted in a >4-fold reduction in enzymatic activity (48). Mutagenesis studies to examine the precise role of Cys-266 in ScGCL function using both in vitro and in vivo approaches are ongoing.

Despite its inclusion in crystallization trials, cysteine was not observed in either ScGCL complex. Examination of the ScGCL structure suggests a possible cysteine binding site adjacent to the bound glutamate substrate. Glu-96 likely forms a hydrogen bond with the α-amino group of the incoming cysteine residue. The side chains of Trp-445 and Arg-196 both point into the putative l-cysteine binding site, and either residue may form a hydrogen bond with the α-carboxylate of l-cysteine. A hydrophobic pocket, lined by Tyr-97, Phe-197, Leu-200, Met-258, and Met-262, could accommodate the sulfhydryl group. Additional studies of ScGCL are required to ascertain the precise recognition mechanisms critical for cysteine binding.

Conflicting catalytic mechanisms have been postulated for GCL. Early studies using the rat homologue suggested a quaternary complex in which ATP/Mg\(^{2+}\) binds first, followed by l-glutamate and l-cysteine in random order (20, 49). Recent comprehensive reports support a random ter-reactant mechanism in the T. brucei and Arabidopsis thaliana enzymes (46, 50). Examination of the reported ScGCL structures suggests that the active site is large enough to accommodate ATP, Mg\(^{2+}\), glutamate, and cysteine simultaneously. However, the glutamate-binding pocket would be completely obstructed if ATP/
Homology modeling of human glutamate cysteine ligase. The folded structure of hGCLC was modeled with PDBViewer software package using the determined ScGCL structure. Panel A, the overall structure of hGCLC is shown in ribbon representation with β-strands colored in yellow, α-helices in blue, and loop regions in gray. Areas with low sequence identity to ScGCL are highlighted in green and represent regions of low model confidence. Cysteine residues are shown in ball and stick representation and amino acid residues with associated clinical mutations are colored in red. For reference, ATP was also docked within the model. Panel B, R127C mutation would disrupt a critical structural salt bridge between Arg-127 and Asp-49 and negatively impact the active site architecture. Panel C, Pro-158 is located in a loop region on the surface of hGCLC. Substitution with a leucine residue may disorder this loop, potentially impacting interactions with the modifier subunit. Panel D, both His-370 and Pro-414 are in close proximitly to a β-strand containing Lys-412, which, based on comparison to ScGCL, is likely involved in orienting the β-phosphate of ATP. The H370L mutation would likely lead to the loss of two ordered water molecules which form hydrogen bonds that stabilize this region of the structure. Similarly, P414L would disrupt this region of the protein and negatively impact ATP binding.
directly in the enzyme active site, these residues, as well as proximal residues, are highly conserved in higher eukaryotic GCL, including ScGCL. The exception is Pro-158. Analysis of the ScGCL structures and the hGCLC homology model suggests the molecular details of diminished catalytic activity.

Mutation of Arg-127 to a cysteine residue (Fig. 4B) would disrupt a salt bridge with Asp-49 and negatively impact the active site architecture. The backbone carbonyls of Asp-49 and Gly-48 contribute to the ATP binding site (similar to ScGCL in Fig. 3A) and Glu-50 is a critical catalytic residue. In addition, the Arg-127—Asp-49 salt bridge is adjacent to a loop containing Thr-105 and Pro-106 (Fig. 4B), which also contributes to formation of the ATP binding site. Thus, the introduction of disorder in this region by this substitution would negatively impact catalytic efficiency.

Pro-158 is located in a surface exposed loop found in both human GCLC and ScGCL, far removed from the enzyme active site (Fig. 4C). This region exhibits poor sequence conservation, with an isoleucine residue, Ile-170, at the equivalent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution. Pertinent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution. Pertinent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution. Pertinent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution. Pertinent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution. Pertinent position in ScGCL. As such, it is difficult to fully explain the phenotype associated with the P158L substitution.

In summary, the reported complexes of ScGCL provide molecular details of diminished catalytic activity. Further kinetic characterizations of the point mutants to confirm this assertion are needed as previous studies did not report $K_{m(\text{ATP})}$ values for either enzyme (15, 42).

In summary, the reported complexes of ScGCL provide molecular details of diminished catalytic activity. Further kinetic characterizations of the point mutants to confirm this assertion are needed as previous studies did not report $K_{m(\text{ATP})}$ values for either enzyme (15, 42).

Acknowledgments—We thank the BioCARS staff for assistance in x-ray data collection, Dr. Mark Wilson (University of Nebraska) for helpful discussions, and Dr. Melanie Simpson (University of Nebraska) for thoughtful insights and review of the manuscript. We acknowledge Brandi Sommer for preparation of the ScGCL expression construct. Use of the Advanced Photon Source was supported by the United States Department of Energy, Basic Energy Sciences, Office of Science (Contract No. W-31-109-Eng-38). Use of BioCARS Sector 14 was supported by the National Institutes of Health, National Center for Research Resources (RR07707).

REFERENCES

1. Anderson, M. E. (1998) *Chem. Biol. Interact.* 111–112, r 1–14
2. Higashi, T., Tateishi, N., Naruse, A., and Sakamoto, Y. (1977) *Biochem. 82,* 117–124
3. Tateishi, N., Higashi, T., Naruse, A., Nakashima, K., and Shiozaki, H. (1977) *J. Nutr.* 107, 51–60
4. Nicholson, D. W., Ali, A., Klemba, M. W., Munday, N. A., Zamboni, R. J., and Ford-Hutchinson, A. W. (1992) *J. Biol. Chem.* 267, 17849–17857
5. Christ-Hazelhof, E., Nugteren, D. H., and Van Dorp, D. A. (1976) *Biochem. Biophys. Acta* 450, 450–461
6. Lu, S. C. (1999) *FASEB J.* 13, 1169–1183
7. Bluh, R., Jaffe, H. A., Holroyd, K. J., Wells, F. B., Maistrangeli, A., Saltini, C., Cantin, A. M., and Crystal, R. G. (1989) *Lancet* 2, 1294–1298
8. Staal, F. J., Roederer, M., and Herzenberg, L. A. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 9943–9947
9. Sofic, E., Lange, K. W., Jellinger, K., and Riederer, P. (1992) *Neurosci. Lett.* 142, 128–130
10. Andersen, J. K., Mo, J. Q., Hom, D. G., Lee, F. Y., Harnish, P., Hamill, R. W., and McNeill, T. H. (1992) *J. Neurochem.* 67, 2164–2171
11. Townsend, D. M., Tew, K. D., and Tapiero, H. (2003) *Biomed. Pharmacother.* 57, 145–155
12. Huyhn, T. T., Huyhn, V. T., Harmon, M. A., and Phillips, M. A. (2003) *J. Biol. Chem.* 278, 39794–39800
13. Walsh, A. C., Li, W., Rosen, D. R., and Lawrence, D. A. (1996) *Cytogenet. Cell Genet.* 75, 14–16
14. Beutler, E., Gelbart, T., Kondo, T., and Matsunaga, A. T. (1999) *Blood* 94, 2890–2894
15. Gysin, R., Kraftsik, R., Sandell, J., Bovet, P., Chappuis, C., Conus, P., Deppen, P., Preisig, M., Ruiz, V., Steullet, P., Tosis, M., Werge, T., Cuénot, M., and Do, K. Q. (2007) *Proc. Natl. Acad. Sci. U.S.A.* 104, 16621–16626
16. Griffith, O. W., and Mulcahy, R. T. (1999) *Adv. Enzymol. Relat. Areas Mol. Biol.* 73, 209–267, xii
17. Strunmeyer, D. H., and Bloch, K. (1960) *J. Biol. Chem.* 235, PC27
18. Orlowski, M., and Meister, A. (1971) *J. Biol. Chem.* 246, 7095–7105
19. Yip, B., and Rudolph, F. B. (1976) *J. Biol. Chem.* 251, 3563–3568
20. Tateishi, N., Higashi, T., Shinya, N., Naruse, A., and Sakamoto, Y. (1974) *J. Biochem.* 75, 93–103
21. Richman, P. G., and Meister, A. (1975) *J. Biol. Chem.* 250, 1422–1426
22. Lu, S. C. (2009) *Mol. Aspects Med.* 30, 42–59
23. Copley, S. D., and Dhillion, J. K. (2002) *Genome Biol.* 3, research0025
24. Hibi, T., Nii, H., Nakatsu, T., Kimura, A., Kato, H., Hiratake, J., and Oda, J. (2004) *Proc. Natl. Acad. Sci. U.S.A.* 101, 15052–15057
25. Hothorn, M., Wachter, A., Gromes, R., Stuwe, T., Tausch, T., and Schefzek, K. (2006) *J. Biol. Chem.* 281, 27557–27565
26. Ohtake, Y., and Yabuuchi, S. (1991) *Eur. J. Pharmacol.* 2164–2171
27. Hibi, T., Nii, H., Nakatsu, T., Kimura, A., Kato, H., Hiratake, J., and Oda, J. (2004) *Proc. Natl. Acad. Sci. U.S.A.* 101, 15052–15057
28. Ghaemmaghami, S., Huh, K. W., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O’Shea, E. K., and Weissman, J. S. (2003) *Nature* 425, 737–741
29. Gill, S. C., and von Hippel, P. H. (1989) *Annu. Rev. Biochem.* 58, 319–326
30. Huang, C. S., Chang, L. S., Anderson, M. E., and Meister, A. (1993) *J. Biol. Chem.* 268, 16765–16780
31. Rodgers, D. W. (1994) *Structure* 2, 1135–1140
32. Ortwinowski, Z., and Minor, W. (1997) *Methods Enzymol.* 276, 307–326
Structure of Glutamate Cysteine Ligase